Zhang becomes CSO at Aspen

Xiaokui Zhang became CSO at Aspen Neuroscience Inc., which is developing neuron replacement therapies to treat Parkinson’s disease. Zhang was EVP and CSO at Celularity Inc. (NASDAQ:CELU), and held several senior roles in the cellular therapeutics unit of Celgene for over a period of 11 years.

Cardiopulmonary disease company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) hired Jonathan Birchall as chief commercial officer to support the U.S. launch of bentracimab.  Birchall joins from Genentech Inc., where he held various roles for 12 years, most recently as VP and head of the company’s thrombolytics franchise. PhaseBio plans to submit a BLA in mid-2022. ...